Epoetin Beta
Active ingredient
Sold as NeoRecormon
- Drug class
- -
- Availability
- See label
- Markets covered
- 2
- Products on record
- 14
Overview
Epoetin Beta is an active pharmaceutical ingredient. The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 13 | March 27, 2026 |
| EU European Union | EMA | 1 | May 2, 2025 |
GBUnited Kingdom· MHRA
13 products
Uses
NeoRecormon is indicated for: - Treatment of symptomatic anaemia associated with chronic renal failure in adult and paediatric patients. - Prevention of anaemia of prematurity in infants with a birth weight of 750 to 1500 g and a gestational age of less than 34 weeks.
- Treatment of symptomatic anaemia in adult patients with non-myeloid malignancies receiving chemotherapy. - Increasing the yield of autologous blood from patients in a pre-donation programme. Its use in this indication must be balanced against the reported increased risk of thromboembolic events.
07 mmol/l], no iron deficiency) if blood conserving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males).
1
EUEuropean Union· EMA
1 product
Uses
NeoRecormon is indicated for: - Treatment of symptomatic anaemia associated with chronic renal failure in adult and paediatric patients. - Prevention of anaemia of prematurity in infants with a birth weight of 750 to 1 500 g and a gestational age of less than 34 weeks.
- Treatment of symptomatic anaemia in adult patients with non-myeloid malignancies receiving chemotherapy. - Increasing the yield of autologous blood from patients in a pre-donation programme. Its use in this indication must be balanced against the reported increased risk of thromboembolic events.
07 mmol/l], no iron deficiency) if blood conserving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males).
1
Sources & citations
- [1]MHRA (UK) · PLGB000310887 · revised February 27, 2026
- [2]European Medicines Agency · EMEA/H/C/000116 · revised May 2, 2025
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.